Nanomedicine Market by Products (Therapeutics, Vaccines, In-vitro Diagnostics, In-vivo Diagnostics, and Regenerative Medicine), Applications (Orthopedics, Infectious Diseases, Clinical Oncology, Clinical Cardiology, and Others), Nanomolecule Types (Nanodevices, Nanotubes, Nanoshells, Nanoparticles [Liposomes, Inorganic Nanoparticles, Polymers & Polymer Drug Conjugates, Dendrimers, Hydrogel Nanoparticles, and Metal & Metal Oxide Nanoparticles {Types (Silver Nanoparticles, Gold Nanoparticles, Iron Oxide Nanoparticles, Gadolinium Oxide Nanoparticles, Alumina Nanoparticles, and Others), Applications (In-vitro Assays, In-vivo Imaging, Proton Therapy, Cell & Phantom Imaging, Targeted Drug Delivery)}]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028
The global nanomedicine market size is projected to register a substantial CAGR during the forecast period attributed to the advancement of technology conjugated with various applications that are relevant and helpful in the early diagnosis and prevention of chronic and acute disorders. Chemicals at nanometric scale and miniaturization of large structures are involved in nanotechnology.
Nanomedicine refers to the application of nanotechnology for medicinal purposes to provide improvement of human health. Using nanomedicine, the players are providing solutions for several life-threatening diseases including diabetes, cancer, Alzheimer’s disease, orthopedic diseases, Parkinson’s disease, and diseases related to the lungs, blood, and cardiovascular system. As per the reports by the Alzheimer's Disease International, there are nearly 50 million individuals suffering from dementia in 2020 and this figure is estimated to double every 20 years.
The COVID-19 pandemic outbreak had a positive impact on the nanomedicine market attributed to the ability of nanotechnology to develop unique strategies for the diagnosis, treatment, and prevention of the coronavirus. The treatment and development of vaccines for COVID-19 management were done by the usage of nano-based materials including equipment for personal protection, nanocarrier systems, disinfectants, and diagnostics system. Rising experimental studies by scientists show that nanomedicine has been proven effective in the development of vaccines and can also be effective in dealing with the virus.
Market Trends, Drivers, Restraints, and Opportunities
- Wide prevalence of cancer, cardiovascular, and genetic diseases is anticipated to fuel the growth of the market during the forecast period.
- Increase in healthcare initiatives taken by government organizations results in various developments in nanorobotics. Some of the key players are trying to target only the cancer cell with having no effect on surrounding non-cancer cells. This is expected to drive the market expansion in the coming years.
- Application of nanotechnology that is capable to deliver in the therapeutic sector and as well as in the diagnostic along with the application of DNA origami in healthcare are anticipated to propel the market growth.
- High cost of nanomedicines and strict & rigid regulations for commercialization of products are key challenges that are estimated to restrain the growth of the market.
- Development of advanced nanomolecules and advancement of technology associated with it are helping in the establishment of a potential pipeline for products. This is projected to create lucrative opportunities for the growth of the market.
Scope of the Report
The report on the global protein expression market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Nanomedicine Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Products (Therapeutics, Vaccines, In-vitro Diagnostics, In-vivo Diagnostics, and Regenerative Medicine), Applications (Orthopedics, Infectious Diseases, Clinical Oncology, Clinical Cardiology, and Others), and Nanomolecule Types (Nanodevices, Nanotubes, Nanoshells, Nanoparticles [Liposomes, Inorganic Nanoparticles, Polymers & Polymer Drug Conjugates, Dendrimers, Hydrogel Nanoparticles, and Metal & Metal Oxide Nanoparticles {Types (Silver Nanoparticles, Gold Nanoparticles, Iron Oxide nanoparticles, Gadolinium Oxide Nanoparticles, Alumina Nanoparticles, and Others), Applications (In-vitro Assays, In-vivo Imaging, Proton Therapy, Cell & Phantom Imaging, and Targeted Drug Delivery)}]) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Pfizer Inc.; Ablynx NV; Nanosphere, Inc.; Abraxis Bioscience Inc.; Teva Pharmaceutical Industries Ltd.; GE Healthcare; Merck & Co. Inc.; Arrowhead Research; Celgene Corp.; and Combimatrix Corp. |
Market Segment Insights
Therapeutics segment is expected to expand at a considerable growth rate
On the basis of products, the global nanomedicine market is divided into therapeutics, vaccines, in-vitro diagnostics, in-vivo diagnostics, and regenerative medicine. The therapeutics segment held a major share of the market in 2019 and is expected to expand at a considerable growth rate due to the presence of several products available associated with various therapeutic methods. Nanoparticles exhibit a unique property of physiochemical which is a proven technology to deliver the drugs at the required site of action. The drugs that are delivered using nanotechnology are less toxic and have excellent advantages.
Clinical cardiology segment is anticipated to grow at a fast pace
Based on applications, the market is segmented into orthopedics, infectious diseases, clinical oncology, clinical cardiology, and others. The oncology segment held a large revenue share of the market in 2020 and is anticipated to exhibit a robust growth rate during the projected period due to the presence of plenty of products in the clinical phases of development for the treatment of cancer. On the other hand, the clinical cardiology segment is anticipated to grow a fast pace in the coming years attributed to the existence of opportunities including tissue generation implantation, stents that are nanostructured, and therapeutic nanovectors.
Nanoparticles segment is estimated to register a high CAGR
On the basis of nanomolcule types, the nanomedicine market is categorized as nanodevices, nanotubes, nanoshells, and nanoparticles. The nanoparticles segment is further divided into liposomes, inorganic nanoparticles, polymers & polymer-drug conjugates, dendrimers, hydrogel nanoparticles, and metal & metal oxide nanoparticles. The metal & metal oxide nanoparticles segment is bifurcated into types and applications. The types segment is again divided into silver nanoparticles, gold nanoparticles, iron oxide nanoparticles, gadolinium oxide nanoparticles, alumina nanoparticles, and others. Meanwhile, the applications segment is sub-divided into in-vitro assays, in-vivo imaging, proton therapy, cell & phantom imaging, and targeted drug delivery.
The nanoparticles segment is anticipated to register a high CAGR during the forecast period due to the wide demand for nanoparticles and functionality of these molecules for various medicine applications. However, the metal & metal oxide nanoparticles segment is estimated to represent a major market share in the coming years attributed to their wide usage for diagnostics.
Asia Pacific is anticipated to expand at lucrative growth
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2019 and is projected to account for a large market share in the coming years due to increasing partnerships between startup organizations for nanomedicine. Moreover, rapid advancement of operating enterprises along with the increased spending for research & development and support provided by the government present another key drivers of the regional market growth. On the other hand, the market of Asia Pacific is anticipated to expand at a lucrative growth rate due to an increase in the number of life-threatening diseases and an increase in the research grants in the region.
Segments
Segments Covered in the ReportThe global nanomedicine market has been segmented on the basis of
Products
- Therapeutics
- Vaccines
- In-vitro Diagnostics
- In-vivo Diagnostics
- Regenerative Medicine
- Orthopedics
- Infectious Diseases
- Clinical Oncology
- Clinical Cardiology
- Others
- Nanodevices
- Nanotubes
- Nanoshells
- Nanoparticles
- Liposomes
- Inorganic Nanoparticles
- Polymers & Polymer Drug Conjugates
- Dendrimers
- Hydrogel Nanoparticles
- Metal & Metal Oxide Nanoparticles
- Types
- Silver Nanoparticles
- Gold Nanoparticles
- Iron Oxide nanoparticles
- Gadolinium Oxide Nanoparticles
- Alumina Nanoparticles
- Others
- Applications
- In-vitro Assays
- In-vivo Imaging
- Proton Therapy
- Cell & Phantom Imaging
- Targeted Drug Delivery
- Types
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Pfizer Inc.
- Ablynx NV
- Nanosphere, Inc.
- Abraxis Bioscience Inc.
- Teva Pharmaceutical Industries Ltd.
- GE Healthcare
- Merck & Co. Inc.
- Arrowhead Research
- Celgene Corp.
- Combimatrix Corp.
Competitive Landscape
Key players competing in the global nanomedicine market are Pfizer Inc.; Ablynx NV; Nanosphere, Inc.; Abraxis Bioscience Inc.; Teva Pharmaceutical Industries Ltd.; GE Healthcare; Merck & Co. Inc.; Arrowhead Research; Celgene Corp.; and Combimatrix Corp. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nanomedicine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nanomedicine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nanomedicine Market - Supply Chain
4.5. Global Nanomedicine Market Forecast
4.5.1. Nanomedicine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nanomedicine Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Nanomedicine Market Absolute $ Opportunity
5. Global Nanomedicine Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Nanomedicine Market Size and Volume Forecast by Applications
5.3.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Nanomedicine Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Nanomedicine Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Nanomedicine Demand Share Forecast, 2019-2026
7. North America Nanomedicine Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Nanomedicine Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Nanomedicine Market Size and Volume Forecast by Applications
7.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Nanomedicine Demand Share Forecast, 2019-2026
8. Latin America Nanomedicine Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Nanomedicine Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Nanomedicine Market Size and Volume Forecast by Applications
8.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Nanomedicine Demand Share Forecast, 2019-2026
9. Europe Nanomedicine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Nanomedicine Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Nanomedicine Market Size and Volume Forecast by Applications
9.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Nanomedicine Demand Share Forecast, 2019-2026
10. Asia Pacific Nanomedicine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Nanomedicine Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Nanomedicine Market Size and Volume Forecast by Applications
10.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Nanomedicine Demand Share Forecast, 2019-2026
11. Middle East & Africa Nanomedicine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Nanomedicine Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Nanomedicine Market Size and Volume Forecast by Applications
11.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Nanomedicine Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Nanomedicine Market: Market Share Analysis
12.2. Nanomedicine Distributors and Customers
12.3. Nanomedicine Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Pfizer Inc. Ablynx NV Nanosphere, Inc. Abraxis Bioscience Inc. Teva Pharmaceutical Industries Ltd. GE Healthcare
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nanomedicine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nanomedicine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nanomedicine Market - Supply Chain
4.5. Global Nanomedicine Market Forecast
4.5.1. Nanomedicine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nanomedicine Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Nanomedicine Market Absolute $ Opportunity
5. Global Nanomedicine Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Nanomedicine Market Size and Volume Forecast by Applications
5.3.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Nanomedicine Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Nanomedicine Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Nanomedicine Demand Share Forecast, 2019-2026
7. North America Nanomedicine Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Nanomedicine Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Nanomedicine Market Size and Volume Forecast by Applications
7.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Nanomedicine Demand Share Forecast, 2019-2026
8. Latin America Nanomedicine Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Nanomedicine Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Nanomedicine Market Size and Volume Forecast by Applications
8.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Nanomedicine Demand Share Forecast, 2019-2026
9. Europe Nanomedicine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Nanomedicine Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Nanomedicine Market Size and Volume Forecast by Applications
9.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Nanomedicine Demand Share Forecast, 2019-2026
10. Asia Pacific Nanomedicine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Nanomedicine Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Nanomedicine Market Size and Volume Forecast by Applications
10.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Nanomedicine Demand Share Forecast, 2019-2026
11. Middle East & Africa Nanomedicine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Nanomedicine Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Nanomedicine Market Size and Volume Forecast by Applications
11.4.1. Orthopedics Infectious Diseases Clinical Oncology Clinical Cardiology Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Nanomedicine Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Nanomedicine Market: Market Share Analysis
12.2. Nanomedicine Distributors and Customers
12.3. Nanomedicine Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Pfizer Inc. Ablynx NV Nanosphere, Inc. Abraxis Bioscience Inc. Teva Pharmaceutical Industries Ltd. GE Healthcare
Segments Covered in the Report
The global nanomedicine market has been segmented on the basis of
Products
The global nanomedicine market has been segmented on the basis of
Products
- Therapeutics
- Vaccines
- In-vitro Diagnostics
- In-vivo Diagnostics
- Regenerative Medicine
- Orthopedics
- Infectious Diseases
- Clinical Oncology
- Clinical Cardiology
- Others
- Nanodevices
- Nanotubes
- Nanoshells
- Nanoparticles
- Liposomes
- Inorganic Nanoparticles
- Polymers & Polymer Drug Conjugates
- Dendrimers
- Hydrogel Nanoparticles
- Metal & Metal Oxide Nanoparticles
- Types
- Silver Nanoparticles
- Gold Nanoparticles
- Iron Oxide nanoparticles
- Gadolinium Oxide Nanoparticles
- Alumina Nanoparticles
- Others
- Applications
- In-vitro Assays
- In-vivo Imaging
- Proton Therapy
- Cell & Phantom Imaging
- Targeted Drug Delivery
- Types
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Pfizer Inc.
- Ablynx NV
- Nanosphere, Inc.
- Abraxis Bioscience Inc.
- Teva Pharmaceutical Industries Ltd.
- GE Healthcare
- Merck & Co. Inc.
- Arrowhead Research
- Celgene Corp.
- Combimatrix Corp.
Key players competing in the global nanomedicine market are Pfizer Inc.; Ablynx NV; Nanosphere, Inc.; Abraxis Bioscience Inc.; Teva Pharmaceutical Industries Ltd.; GE Healthcare; Merck & Co. Inc.; Arrowhead Research; Celgene Corp.; and Combimatrix Corp. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.
Our Clients
Related Reports
Some other reports from this category!
